• Botulinum toxin has demonstrated utility across dozens of published uses expected to be accessible to ABP-450; accelerated and simplified commercialization timeline due to existing aesthetic BLA (separately held by Evolus) and manufacturing site approved by FDA, EMA and Health Canada.
  • Single existing competitor for key target markets (episodic & chronic migraine); unlike in aesthetic market, ABP-450’s therapeutic focus will compete with market leader on a product-to-product basis, not against a portfolio of products.
  • Episodic migraine approval would nearly triple the current addressable patient population (Botox®indicated for chronic migraine only); ABP-450 Phase 2 migraine study includes chronic and episodic migraine patients with a streamlined injection protocol with potential to enhance safety and tolerability.
  • Ongoing pre-clinical program utilizing proprietary injection paradigm in a novel part of the anatomy is designed to provide IND supporting safety and efficacy data; this innovative approach has the potential for utility across a broad Neuro/Psych portfolio including PTSD.
  • Potential to pursue traditional pharma pricing model currently not pursued by therapeutic toxin competition with a 900 kDabotulinum toxin expected to facilitate physician adoption
  • Significant neurotoxin commercial and clinical development experience among management team translating to approximately $124M invested in AEON since 2019.